Publications (317) Alfonso Jesús Domínguez-Gil Hurlé publications

filter_list

2022

  1. Iniciación a la toxicocinética desde la Real Academia Nacional de Farmacia: Un ejemplo de colaboración académica

    Anales de la Real Academia Nacional de Farmacia, Núm. 5, pp. 455-468

2017

  1. Differences between agalsidase α and agalsidase β in the treatment of Fabry disease

    Medicina Clinica

  2. Medicamentos Falsificados. Todo lo que debemos saber

    Farmajournal, Vol. 2, Núm. 1, pp. 135-136

  3. Otitis, Antibióticos, Homeopatía y Farmacia

    Farmajournal, Vol. 2, Núm. 2, pp. 21-23

  4. Tailored botulinum toxin type A injections in aesthetic medicine: Consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone

    Clinical, Cosmetic and Investigational Dermatology, Vol. 10, pp. 413-421

2016

  1. A pharmacist's role in the individualization of treatment of HIV patients

    Personalized Medicine, Vol. 13, Núm. 2, pp. 169-188

  2. Anticonceptivos hormonales

    Mecanismos fisiológicos y moleculares de la anticoncepción (Real Academia Nacional de Farmacia), pp. 97-108

  3. Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients

    Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355

  4. Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39

  5. Mecanismos fisiológicos y moleculares de la anticoncepción coord.

    Real Academia Nacional de Farmacia

2015

  1. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman

    Clinical drug investigation, Vol. 35, Núm. 1, pp. 61-66

2014

  1. Facility-based inspection training in a virtual 3D laboratory

    Accreditation and Quality Assurance, Vol. 19, Núm. 5, pp. 403-409

  2. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

  3. Toxicogenetics of lopinavir/ritonavir in HIV-infected European patients

    Personalized Medicine, Vol. 11, Núm. 3, pp. 263-272

2013

  1. Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study

    Patient Preference and Adherence, Vol. 7, pp. 729-739

  2. Impact of pharmacogenetics on CNS side effects related to efavirenz

    Pharmacogenomics, Vol. 14, Núm. 10, pp. 1167-1178

  3. Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43

  4. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy

    Current Drug Metabolism, Vol. 14, Núm. 7, pp. 729-737

2012

  1. Juega a ganar 2.0

    Hospital Universitario de Salamanca

  2. Prucaloprida, nuevo procinético agonista selectivo de receptores de 5HT4: su aportación en el estreñimiento crónico resistente a tratamiento con laxantes

    A. Domínguez-Gil